Thiotepa

Generic Name: Thiotepa

Brand Names: Tepadina, Thiotepa Riemser

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₃PS

CAS Number: 52-24-4

Unique Ingredient Identifier: 905Z5W3GKH

Background: N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.

Indication: ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.

Associated Conditions: Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion

Clinical Trials

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Phase 1

Recruiting

Conditions: Aml
Acute Myeloid Leukemia, Pediatric
Acute Myeloid Leukemia
AML, Childhood

Interventions: Drug: Rabbit Anti thymocyte globulin
Drug: Plerixafor
Biological: Granulocyte Colony-Stimulating Factor
Drug: Busulfan
Drug: Fludarabine
Drug: Thiotepa
Drug: Melphalan
Biological: TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft
Biological: memory-like natural killer cells
Biological: IL-2
Device: CliniMACS

First Posted Date: 2023-12-06

Last Posted Date: 2025-05-20

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 48

Registration Number: NCT06158828

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Phase 2

Recruiting

Conditions: Acute Leukemia of Ambiguous Lineage
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Blastic Plasmacytoid Dendritic Cell Neoplasm
Hematopoietic and Lymphatic System Neoplasm
Mixed Phenotype Acute Leukemia
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Non-Hodgkin Lymphoma
Chronic Myeloid Leukemia, BCR-ABL1 Positive

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspirate
Drug: Cyclophosphamide
Drug: Cyclosporine
Procedure: Diagnostic Imaging
Procedure: Echocardiography
Drug: Fludarabine Phosphate
Procedure: Multigated Acquisition Scan
Drug: Mycophenolate Mofetil
Other: Survey Administration
Radiation: Total-Body Irradiation
Drug: Thiotepa
Procedure: Umbilical Cord Blood Transplantation

First Posted Date: 2023-08-28

Last Posted Date: 2025-01-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 54

Registration Number: NCT06013423

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.

Phase 2

Recruiting

Conditions: Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma

Interventions: Drug: thiotepa combined with pomalidomide

First Posted Date: 2023-07-05

Last Posted Date: 2023-07-05

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 28

Registration Number: NCT05931328

Locations: 🇨🇳
Jiangsu Province People's Hospital., Nanjing, Jiangsu, China

Thiotepa Incorporating TBI/Cy Conditioning Regimen for EBV-HLH With Central Nervous System Involvement

Not Applicable

Recruiting

Conditions: HLH

Interventions: Drug: Thiotepa

First Posted Date: 2023-05-11

Last Posted Date: 2023-05-11

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 20

Registration Number: NCT05854225

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies

Phase 2

Terminated

Conditions: Myeloid Malignancy
Hematologic Malignancy

Interventions: Drug: Ruxolitinib
Drug: Anti-thymocyte globulin (ATG)
Drug: Mesna
Drug: Cyclosporine
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Methotrexate
Radiation: Total Body Irradiation (radiation treatment)
Drug: Busulfan
Drug: Bone marrow infusion
Drug: Thiotepa

First Posted Date: 2022-10-14

Last Posted Date: 2024-07-10

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 3

Registration Number: NCT05579769

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

CD34+ Transplants for Leukemia and Lymphoma

Phase 2

Not yet recruiting

Conditions: Leukemia, Lymphocytic, Acute
Leukemia, Myeloid, Acute

Interventions: Radiation: Total Body Irradiation (TBI)
Drug: Busulfan
Drug: Thiotepa
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2022-10-04

Last Posted Date: 2025-04-15

Lead Sponsor: Guenther Koehne

Target Recruit Count: 100

Registration Number: NCT05565105

Locations: 🇺🇸
Baptist Health South Florida/Miami Cancer Institute, Miami, Florida, United States

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Phase 3

Active, not recruiting

Conditions: Mixed Phenotype Acute Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Drug: Busulfan
Drug: Cyclophosphamide
Procedure: Echocardiography Test
Drug: Fludarabine
Procedure: Haploidentical Hematopoietic Cell Transplantation
Biological: Lapine T-Lymphocyte Immune Globulin
Procedure: Lumbar Puncture
Procedure: Matched Unrelated Donor Hematopoietic Cell Transplantation
Drug: Melphalan
Drug: Methotrexate
Procedure: Multigated Acquisition Scan
Drug: Mycophenolate Mofetil
Procedure: Myeloablative Conditioning
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Tacrolimus
Drug: Thiotepa
Biological: Rituximab
Radiation: Total-Body Irradiation
Procedure: T-Cell Depletion Therapy

First Posted Date: 2022-07-14

Last Posted Date: 2025-05-08

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 435

Registration Number: NCT05457556

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
C S Mott Children's Hospital, Ann Arbor, Michigan, United States
🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States

and more 60 locations

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Phase 2

Not yet recruiting

Conditions: Neuroblastoma

Interventions: Drug: Anti Thymocyte Globulin
Drug: Fludarabine
Drug: Cyclophosphamide injection
Drug: Topotecan
Drug: Melphalan
Drug: Thiotepa
Drug: Busulfan
Drug: Cyclosporine
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: Methotrexate

First Posted Date: 2022-03-31

Last Posted Date: 2022-07-01

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 64

Registration Number: NCT05303727

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Phase 1

Recruiting

Conditions: Allogeneic Hematopoietic Cell Transplantation (HCT)
Advanced Hematologic Malignancies
Acute Leukemia
Chronic Myelogenous Leukemia
Myelodysplastic Syndromes
Myeloproliferative Disorders